DS86760016 (DS 86760016)
- CAS No.
- 1853176-89-2
- Chemical Name:
- DS86760016 (DS 86760016)
- Synonyms
- DS86760016;DS86760016 hydrochloride;DS86760016 (DS 86760016)
- CBNumber:
- CB74844733
- Molecular Formula:
- C9H11BClNO4
- Molecular Weight:
- 243.45
- MDL Number:
- MOL File:
- 1853176-89-2.mol
- MSDS File:
- SDS
DS86760016 (DS 86760016) price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0087306 | DS86760016 99.25% | 1853176-89-2 | 1mg | $883 | 2026-06-04 | Buy |
| ChemScene | CS-0087306 | DS86760016 99.25% | 1853176-89-2 | 5mg | $2649 | 2026-06-04 | Buy |
| ChemScene | CS-0087306 | DS86760016 99.25% | 1853176-89-2 | 10mg | $4241 | 2026-06-04 | Buy |
| ApexBio Technology | BA1518 | DS86760016 | 1853176-89-2 | 1mg | $360 | 2026-05-06 | Buy |
| ApexBio Technology | BA1518 | DS86760016 | 1853176-89-2 | 5mg | $900 | 2026-05-06 | Buy |
DS86760016 (DS 86760016) Chemical Properties,Uses,Production
Uses
DS86760016 is a potent leucyl-tRNA synthetase (LeuRS) inhibitor with activity against multidrug-resistant (MDR) Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. DS86760016 inhibits LeuRS enzymes from Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, with IC50s of 0.38, 0.62, and 0.16 μM, respectively[1][2].
Biological Activity
DS86760016 is a potent leucyl-tRNA synthetase (LeuRS) inhibitor with activity against multidrug-resistant (MDR) Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. DS86760016 inhibits LeuRS enzymes from Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, with IC50s of 0.38, 0.62, and 0.16 μM, respectively[1][2]. DS86760016 inhibits some Gram-negative bacteria with an MICs ranging from 0.25 to 2 μg/ml. The MIC of DS86760016 against Gram-positive bacteria is >32 μg/ml. DS86760016 is active against both susceptible and these MDR P. aeruginosa, E. coli, and K. pneumoniae strains, with an MIC90 of 2 μg/ml[1]. DS86760016 (7.5-220 mg/kg; s.c.; q6h for 7 days) shows moderate spontaneous resistance (FSR)[1].The pharmacokinetic (PK) parameters of DS86760016 in mouse, rat, monkey, and dog plasma by the intravenous (i.v.) route are test. DS86760016 shows lower intravenous plasma clearances (CLp) of 11, 29, 5.6, and 4.5 ml/min/kg in mouse, rat, monkey, and dog plasma, respectively. The plasma half-lives (t1/2) for DS86760016 are 1.9, 1.5, 8.6, and 8.3 h in mice, rats, monkeys, and dogs, respectively. The lower plasma clearance resulted in higher plasma exposures for DS86760016, with dose-normalized areas under the curve after i.v. administration (DNAUCIVs) of 1.5, 0.6, 3.7, and 3.0 μg h kg/ml/mg in mice, rats, monkeys, and dogs, respectively[1].
in vivo
DS86760016 (7.5-220 mg/kg; s.c.; q6h for 7 days) shows moderate spontaneous resistance (FSR)[1].
The pharmacokinetic (PK) parameters of DS86760016 in mouse, rat, monkey, and dog plasma by the intravenous (i.v.) route are test. DS86760016 shows lower intravenous plasma clearances (CLp) of 11, 29, 5.6, and 4.5 ml/min/kg in mouse, rat, monkey, and dog plasma, respectively. The plasma half-lives (t1/2) for DS86760016 are 1.9, 1.5, 8.6, and 8.3 h in mice, rats, monkeys, and dogs, respectively. The lower plasma clearance resulted in higher plasma exposures for DS86760016, with dose-normalized areas under the curve after i.v. administration (DNAUCIVs) of 1.5, 0.6, 3.7, and 3.0 μg h kg/ml/mg in mice, rats, monkeys, and dogs, respectively[1].
| Animal Model: | Immunocompetent female Swiss Webster mice (urinary tract infection, UTI model)[1] |
| Dosage: | 7.5, 30, 220 mg/kg |
| Administration: | S.c.; q6h for 7 days |
| Result: | Bacteria resistant to DS86760016 were detected in a few animals after 1 day of treatment at doses of 7.5 and 30 mg/kg q6h; however, no resistant bacteria were detected at these doses after 7 days of treatment. No resistance was observed in any of the mice treated at a dose of 220 mg/kg q6h. |
References
[1]. Purnapatre KP, et al. In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens. Antimicrob Agents Chemother. 2018;62(4):e01987-17. Published 2018 Mar 27.[2]. Kumar M, et al. DS86760016, a Leucyl-tRNA Synthetase Inhibitor with Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(4):e02122-18. Published 2019 Mar 27.
DS86760016 (DS 86760016) Preparation Products And Raw materials
Raw materials
Preparation Products
DS86760016 (DS 86760016) Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6288 | 58 |
| Nanjing Shizhou Biology Technology Co.,Ltd | 025-85560043 15850508050 | cindy.huang@synzest.com | China | 11975 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Guangzhou Ruidi Biotechnology Co., Ltd. | 020-82099279 18988941402 | sales@ubiochem.com | China | 10000 | 58 |
| Supplier | Advantage |
|---|---|
| BOC Sciences | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 58 |
| Nanjing Shizhou Biology Technology Co.,Ltd | 58 |
| TargetMol Chemicals Inc. | 58 |
| Guangzhou Ruidi Biotechnology Co., Ltd. | 58 |
